AbbVie Inc. (ABBV) Stock Analysis and Metrics

AbbVie

NYSE: ABBV

$254.49 ▲ +0.10 (+0.04%)

At close: Jul 17, 2026 · 4:02 PM UTC

Financial Ratios

Market Cap444.34 Bn

P/E122.04

P/S7.07

Div. Yield0.03

ROIC (Qtr)0.00

Total Debt (Qtr)64.53 Bn

Revenue Growth (1y) (Qtr)12.43

Add ratio to table…

About

AbbVie Inc. is a global, diversified research-based biopharmaceutical company dedicated to the development and commercialization of innovative medicines and therapies for complex and serious diseases. The company focuses its efforts on immunology, neuroscience, oncology, and aesthetics, leveraging its expertise in research and innovation to address significant unmet medical needs worldwide. AbbVie integrates research and development, manufacturing, commercialization, and sales into a cohesive global operation aimed at delivering advanced therapeutic solutions to patients and healthcare providers.

AbbVie generates revenue primarily through the sale of its pharmaceutical products across therapeutic areas. Key revenue drivers include immunology treatments such as Skyrizi, Rinvoq, and Humira; neuroscience products like Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta; oncology therapies including Imbruvica, Venclexta, and Elahere; and aesthetics offerings such as Botox Cosmetic and the Juvederm Collection. The company also earns revenue from eye care products like Ozurdex and Lumigan/Ganfort, as well as other key products such as Mavyret for hepatitis C, Creon for pancreatic insufficiency, and Linzess/Constella for gastrointestinal conditions. AbbVie sells its products globally to wholesalers, distributors, government agencies, healthcare facilities, specialty pharmacies, independent retailers, and directly to physicians and licensed healthcare providers for certain products.

AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization, and sale of innovative medicines and therapies.

• AbbVie's single global segment encompasses the discovery and development of new compounds, the manufacturing and supply of products, and the coordination of commercial efforts including marketing, sales, and distribution of its medicines and therapies across immunology, neuroscience, oncology, aesthetics, and eye care.

AbbVie holds a strong competitive position in the biopharmaceutical industry, particularly in immunology where its Skyrizi and Rinvoq products have demonstrated leadership in treating autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. The company faces competition from other research-based pharmaceutical and biotechnology firms developing IL-23 inhibitors, JAK inhibitors, biosimilars, and targeted therapies in oncology. AbbVie maintains advantages through its robust pipeline, deep expertise in biologics and small molecules, significant investment in research and development, and intellectual property protection for key products such as risankizumab and upadacitinib, with composition of matter patents expected to expire in 2033. Additionally, its diversified portfolio across high-need therapeutic areas reduces reliance on any single product or market.

AbbVie serves a diverse customer base including physicians, external experts, healthcare providers, managed care organizations such as health maintenance organizations and pharmacy benefit managers, hospitals, and state and federal government agencies including Medicaid programs, the Department of Veterans Affairs, and the Department of Defense. The company also engages in direct-to-consumer marketing for certain products where appropriate and permitted by regulation. AbbVie's products are distributed through wholesalers and distributors, with McKesson Corporation, Cardinal Health Inc., and Cencora Inc. accounting for substantially all of its pharmaceutical product sales in the United States.

Investment Thesis

▲ Bull case

AbbVie's strategic expansion into oncology through innovative platforms like antibody-drug conjugates (ADCs) and T-cell engagers is creating significant long-term value, as evidenced by the FDA approval of DECNUPAZ for BPDCN and positive CHMP opinions for etentamig in multiple myeloma and amyloidosis, which demonstrate the company's ability to address ultra-rare and refractory hematologic malignancies with differentiated mechanisms; the Phase 1/2 CADENZA trial showed a 69.7% composite complete response rate in newly diagnosed BPDCN patients with a median duration of response of 9.7 months, and 39.4% of these patients proceeded to stem cell transplant, indicating DECNUPAZ's potential to enable curative pathways in a population with historically limited options, while the ADC and TCE platforms are being evaluated across solid tumors including prostate, ovarian, and lung cancers, suggesting a broad pipeline beyond hematology that could drive future growth as Humira declines.
The company's immunology franchise remains a durable growth engine, with Skyrizi and Rinvoq delivering strong quarterly results that exceeded expectations—Skyrizi Q1 2026 sales reached $4.48 billion, up 30.9% year-over-year, and Rinvoq sales rose to $2.12 billion, up 23.3%—supported by expanding label indications such as the FDA submission for subcutaneous induction of Skyrizi in Crohn's disease and positive CHMP opinions for Rinvoq in alopecia areata and vitiligo, which together address large unmet markets; the AFFIRM study showed 55% of patients achieved clinical remission with Skyrizi SC induction versus 30% on placebo, and 67% of responders maintained remission at week 24, reinforcing its efficacy in difficult-to-treat populations, while real-world data from DDW demonstrated low switch rates and reduced hospitalization odds, indicating sustained adherence and clinical benefit that could support premium pricing and market share gains in IBD and dermatology.
AbbVie's $1.4 billion investment in the Durham, North Carolina manufacturing campus represents a strategic move to secure long-term supply chain resilience and capacity for high-growth immunology, neuroscience, and oncology products, particularly small volume parenterals (SVPs) like prefilled syringes and cartridges used for Skyrizi and Rinvoq, with completion expected by end-2028 and plans to hire 734 employees; this investment is part of a broader $100 billion U.S. R&D and capital commitment over the next decade, which includes prior investments like the $380 million for API facilities in Illinois, positioning AbbVie to mitigate risks from geopolitical trade tensions and tariffs while supporting scalable production for its pipeline, including potential blockbusters from the Apogee acquisition such as zumilokibart for atopic dermatitis and asthma, which could benefit from domestic manufacturing scale to meet future demand without reliance on external suppliers.
The proposed acquisition of Apogee Therapeutics for $10.9 billion equity value adds significant near-term catalyst potential to AbbVie's immunology pipeline, particularly in high-unmet-need areas like atopic dermatitis and asthma, where zumilokibart (APG777) showed approximately two-thirds of patients achieving significant skin clearance at 16 weeks in Phase 2 trials with notable itch reduction and the potential for quarterly or twice-yearly dosing regimens, offering both efficacy and convenience advantages over current therapies; the transaction is expected to be accretive to adjusted diluted EPS beginning in 2032, and with Apogee's broader pipeline targeting validated inflammatory pathways like TSLP and IL-13, AbbVie could rapidly advance these programs using its commercial scale and expertise, creating a differentiated edge in inflammatory diseases where competitors are also facing patent cliffs and seeking external innovation to sustain growth beyond legacy products.

AbbVie's strategic expansion into oncology through innovative platforms like antibody-drug conjugates (ADCs) and T-cell engagers is creating significant long-term value, as evidenced by the FDA approval of DECNUPAZ for BPDCN and positive CHMP opinions for etentamig in multiple myeloma and amyloidosis, which demonstrate the company's ability to address ultra-rare and refractory hematologic malignancies with differentiated mechanisms; the Phase 1/2 CADENZA trial showed a 69.7% composite complete response rate in newly diagnosed BPDCN patients with a median duration of response of 9.7 months, and 39.4% of these patients proceeded to stem cell transplant, indicating DECNUPAZ's potential to enable curative pathways in a population with historically limited options, while the ADC and TCE platforms are being evaluated across solid tumors including prostate, ovarian, and lung cancers, suggesting a broad pipeline beyond hematology that could drive future growth as Humira declines.
The company's immunology franchise remains a durable growth engine, with Skyrizi and Rinvoq delivering strong quarterly results that exceeded expectations—Skyrizi Q1 2026 sales reached $4.48 billion, up 30.9% year-over-year, and Rinvoq sales rose to $2.12 billion, up 23.3%—supported by expanding label indications such as the FDA submission for subcutaneous induction of Skyrizi in Crohn's disease and positive CHMP opinions for Rinvoq in alopecia areata and vitiligo, which together address large unmet markets; the AFFIRM study showed 55% of patients achieved clinical remission with Skyrizi SC induction versus 30% on placebo, and 67% of responders maintained remission at week 24, reinforcing its efficacy in difficult-to-treat populations, while real-world data from DDW demonstrated low switch rates and reduced hospitalization odds, indicating sustained adherence and clinical benefit that could support premium pricing and market share gains in IBD and dermatology.
AbbVie's $1.4 billion investment in the Durham, North Carolina manufacturing campus represents a strategic move to secure long-term supply chain resilience and capacity for high-growth immunology, neuroscience, and oncology products, particularly small volume parenterals (SVPs) like prefilled syringes and cartridges used for Skyrizi and Rinvoq, with completion expected by end-2028 and plans to hire 734 employees; this investment is part of a broader $100 billion U.S. R&D and capital commitment over the next decade, which includes prior investments like the $380 million for API facilities in Illinois, positioning AbbVie to mitigate risks from geopolitical trade tensions and tariffs while supporting scalable production for its pipeline, including potential blockbusters from the Apogee acquisition such as zumilokibart for atopic dermatitis and asthma, which could benefit from domestic manufacturing scale to meet future demand without reliance on external suppliers.
The proposed acquisition of Apogee Therapeutics for $10.9 billion equity value adds significant near-term catalyst potential to AbbVie's immunology pipeline, particularly in high-unmet-need areas like atopic dermatitis and asthma, where zumilokibart (APG777) showed approximately two-thirds of patients achieving significant skin clearance at 16 weeks in Phase 2 trials with notable itch reduction and the potential for quarterly or twice-yearly dosing regimens, offering both efficacy and convenience advantages over current therapies; the transaction is expected to be accretive to adjusted diluted EPS beginning in 2032, and with Apogee's broader pipeline targeting validated inflammatory pathways like TSLP and IL-13, AbbVie could rapidly advance these programs using its commercial scale and expertise, creating a differentiated edge in inflammatory diseases where competitors are also facing patent cliffs and seeking external innovation to sustain growth beyond legacy products.

▼ Bear case

AbbVie's core immunology franchise faces mounting competitive pressure from emerging biosimilars and next-generation therapies that could erode the long-term dominance of Skyrizi and Rinvoq, despite their current strong performance; while Skyrizi Q1 2026 sales grew 30.9% year-over-year to $4.48 billion, this growth is occurring from a smaller base as Humira declines, and the company faces increasing competition in psoriasis and IBD from agents like Tremfya (JNJ) and newer IL-23 or JAK inhibitors with potentially better dosing or safety profiles, particularly as payers intensify formulary management and seek cost-effective alternatives, which could pressure pricing and market share gains even if clinical differentiation remains.
The company's reliance on acquired IPR&D and milestone expenses is creating a significant drag on profitability that may not be sustainable, as evidenced by Q1 2026 GAAP diluted EPS of $0.39 versus adjusted EPS of $2.65, with the $744 million in acquired IPR&D and milestones expense representing an unfavorable impact of $0.41 per share—nearly double the $248 million in the prior year period—suggesting that the pace of deal-driven R&D spending is accelerating, and if this trend continues, it could pressure adjusted margins and raise questions about the quality of internal innovation, especially given that AbbVie raised its full-year 2026 adjusted EPS guidance only modestly despite strong product performance, indicating that external investments are being used to offset slower organic pipeline progress.
AbbVie's oncology portfolio, while expanding through ADC and TCE platforms, remains highly dependent on venetoclax-based combinations, which face increasing competition and potential limitations in broader applicability; although the Phase 3 CLL14 trial showed venetoclax plus obinutuzumab reduced the risk of progression or death by 50% versus chlorambucil plus obinutuzumab with a median PFS of 6.4 years versus 3.2 years, the regimen carries significant risks including tumor lysis syndrome, neutropenia, and infections, and its fixed-duration nature may limit utility in patients requiring continuous therapy, while newer agents like CAR-T therapies and bispecific antibodies are gaining traction in relapsed/refractory settings, potentially diminishing the long-term addressable market for venetoclax combinations even as AbbVie expands into earlier lines of therapy through label expansions in CLL.
The proposed Apogee acquisition, while promising, introduces substantial execution and valuation risks that could undermine shareholder value if not successfully integrated, given the $10.9 billion equity price implies high expectations for pipeline assets like zumilokibart, which is still in Phase 2 for atopic dermatitis and asthma with no guarantee of Phase 3 success or regulatory approval, and the transaction is not expected to be accretive to adjusted EPS until 2032—a distant horizon that exposes AbbVie to prolonged integration challenges, cultural clashes, and potential overpayment if Apogee's clinical data fails to translate into real-world differentiation, particularly in crowded markets like atopic dermatitis where Dupixent (SNY/RVG) and other biologics already hold strong positions, and where oral alternatives could disrupt the injectable landscape that Apogee's pipeline relies upon.

AbbVie's core immunology franchise faces mounting competitive pressure from emerging biosimilars and next-generation therapies that could erode the long-term dominance of Skyrizi and Rinvoq, despite their current strong performance; while Skyrizi Q1 2026 sales grew 30.9% year-over-year to $4.48 billion, this growth is occurring from a smaller base as Humira declines, and the company faces increasing competition in psoriasis and IBD from agents like Tremfya (JNJ) and newer IL-23 or JAK inhibitors with potentially better dosing or safety profiles, particularly as payers intensify formulary management and seek cost-effective alternatives, which could pressure pricing and market share gains even if clinical differentiation remains.
The company's reliance on acquired IPR&D and milestone expenses is creating a significant drag on profitability that may not be sustainable, as evidenced by Q1 2026 GAAP diluted EPS of $0.39 versus adjusted EPS of $2.65, with the $744 million in acquired IPR&D and milestones expense representing an unfavorable impact of $0.41 per share—nearly double the $248 million in the prior year period—suggesting that the pace of deal-driven R&D spending is accelerating, and if this trend continues, it could pressure adjusted margins and raise questions about the quality of internal innovation, especially given that AbbVie raised its full-year 2026 adjusted EPS guidance only modestly despite strong product performance, indicating that external investments are being used to offset slower organic pipeline progress.
AbbVie's oncology portfolio, while expanding through ADC and TCE platforms, remains highly dependent on venetoclax-based combinations, which face increasing competition and potential limitations in broader applicability; although the Phase 3 CLL14 trial showed venetoclax plus obinutuzumab reduced the risk of progression or death by 50% versus chlorambucil plus obinutuzumab with a median PFS of 6.4 years versus 3.2 years, the regimen carries significant risks including tumor lysis syndrome, neutropenia, and infections, and its fixed-duration nature may limit utility in patients requiring continuous therapy, while newer agents like CAR-T therapies and bispecific antibodies are gaining traction in relapsed/refractory settings, potentially diminishing the long-term addressable market for venetoclax combinations even as AbbVie expands into earlier lines of therapy through label expansions in CLL.
The proposed Apogee acquisition, while promising, introduces substantial execution and valuation risks that could undermine shareholder value if not successfully integrated, given the $10.9 billion equity price implies high expectations for pipeline assets like zumilokibart, which is still in Phase 2 for atopic dermatitis and asthma with no guarantee of Phase 3 success or regulatory approval, and the transaction is not expected to be accretive to adjusted EPS until 2032—a distant horizon that exposes AbbVie to prolonged integration challenges, cultural clashes, and potential overpayment if Apogee's clinical data fails to translate into real-world differentiation, particularly in crowded markets like atopic dermatitis where Dupixent (SNY/RVG) and other biologics already hold strong positions, and where oral alternatives could disrupt the injectable landscape that Apogee's pipeline relies upon.

Peer Comparison

Companies in the Drug Manufacturers - General

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,066.16 Bn	42.18	14.76	43.37 Bn
2	JNJ	Johnson & Johnson	611.69 Bn	29.07	6.35	54.99 Bn
3	ABBV	AbbVie Inc.	444.34 Bn	122.04	7.07	64.53 Bn
4	AZN	Astrazeneca Plc	284.94 Bn	23.78	2,793.52	-24.45 Bn
5	MRK	Merck & Co., Inc.	224.23 Bn	25.00	3.41	49.12 Bn
6	AMGN	Amgen Inc	195.12 Bn	25.02	5.24	57.32 Bn
7	GILD	Gilead Sciences, Inc.	156.45 Bn	16.36	5.26	22.17 Bn
8	PFE	Pfizer Inc	136.01 Bn	11,334.57	5.56	64.46 Bn

Research Tools

Developers

About

Investment Thesis

Initial Application Period Cumulative Effect Transition Breakdown of Revenue (2018)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Initial Application Period Cumulative Effect Transition Breakdown of Revenue (2018)

Peer Comparison

Create an account

Sign In

Reset Password